Archive: March 18 2021
Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
CAR-T cells engineered to target a common genetic alteration: Loss of heterozyg...
Researchers developed a prototype for a new cancer immunotherapy that uses engineered T cells to target a genetic alteration common among all cancers.
Frontline Axi-Cel Elicits 74% CR Rate in High-Risk Large B-Cell Lymphoma
Axicabtagene ciloleucel elicited a high objective response rate of 85%, with a complete response rate of 74% when used as a first-line therapy in patients with high-risk large B-cell lymphoma.
Risk-Adapted CAR T Dosing Maintains Efficacy, Improves Safety in Pediatric Relap...
A risk-adapted CD19 CAR T-cell therapy dosing approach allowed pediatric patients with relapsed/refractory acute lymphocytic leukemia to maintain a high rate of remission, while reducing the risk of severe toxicities among those with a high initial disease burden.
Brexucabtagene Autoleucel Displays Continued Durability, Safety in Relapsed/Refr...
Brexucabtagene autoleucel displayed significant and durable responses and a reduction in adverse effects in patients with relapsed/refractory mantle cell lymphoma.
Teclistamab Shows Continued Promise in R/R MM: Updated phase 1 results
Teclistamab demonstrated encouraging clinical activity, along with a tolerable safety profile, in patients with relapsed/refractory multiple myeloma.
Therapeutic options for Treatment-Naïve Chronic Leukocytic Leukemia
During a virtual Targeted Oncology Case-Based Roundtable event, Daniel O. Persky, MD, reviewed the case of a 61-year-old patient with chronic lymphocytic leukemia.